ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > IL23A & IL12B

IL23A & IL12B

概要

Name:Interleukin-23
Target Synonym:Interleukin-23
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

ILB-H82W6-Cell-based assay
 IL23A & IL12B CELL

Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) stimulates secretion of IL-17 by mousespleen cells. The ED50 for this effect is 0.191-0.2173 ng/mL (Routinely tested).

ILB-H82W6-Cell-based assay
 IL23A & IL12B CELL

Cell based assay shows that the secretion of IL-17 induced by Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) is inhibited by increasing concentration of the anti-human IL-23 neutralizing antibody. The IC50 is between 0.25-1.40 ng/mL (Routinely tested).

ILB-H82W6-SPR
 IL23A & IL12B SPR

Captured Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) on Biotin CAP - Series S sensor Chip can bind Human IL-23 R, His Tag (Cat. No. ILR-H52H4) affinity constant of 4.77 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

ILB-H52W5-SPR
 IL23A & IL12B SPR

Captured Human IL-23 R, Fc Tag (Cat. No. ILR-H5254) on CM5 chip via anti-human IgG Fc antibodies surface can bind Human IL-23A&IL-12B Heterodimer Protein, His Tag&Tag Free (Cat. No. ILB-H52W5) with an affinity constant of 5.36 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

IL23A & IL12B Molecule Synonym Name

IL-23 alpha & IL-12 beta

IL23A & IL12B Molecule Background

Interleukin-23 subunit alpha (IL-23 alpha) can associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.

IL23A & IL12B References

相関分子

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ustekinumab CNTO-1275; C-340 Approved Johnson & Johnson Innovative Medicine Stelara, 喜达诺 United States Plaque psoriasis Janssen Biotech Inc 2009-09-25 Arthritis, Juvenile; Crohn Disease; Dermatitis, Atopic; Plaque psoriasis; Hidradenitis Suppurativa; Uveitis; Common Variable Immunodeficiency; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Liver Cirrhosis, Biliary; Multiple Sclerosis; Sjogren's Syndrome; Pouchitis; Ichthyosis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Diabetes Mellitus, Type 1; Polymyositis Details
Ustekinumab biosimilar (Alvotech) AVT04; AVT-04 Approved Alvotech hf Jamteki, Uzpruvo, SELARSDI™ Japan Psoriasis Fuji Pharma Co Ltd 2023-09-25 Psoriasis; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease Details
Ustekinumab biosimilar(Amgen) ABP-654 Approved Amgen Inc Wezlana, WEZLANA United States Crohn Disease; Plaque psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative Amgen Inc 2023-10-31 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details
Ustekinumab CNTO-1275; C-340 Approved Johnson & Johnson Innovative Medicine Stelara, 喜达诺 United States Plaque psoriasis Janssen Biotech Inc 2009-09-25 Arthritis, Juvenile; Crohn Disease; Dermatitis, Atopic; Plaque psoriasis; Hidradenitis Suppurativa; Uveitis; Common Variable Immunodeficiency; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Liver Cirrhosis, Biliary; Multiple Sclerosis; Sjogren's Syndrome; Pouchitis; Ichthyosis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Diabetes Mellitus, Type 1; Polymyositis Details
Ustekinumab biosimilar (Alvotech) AVT04; AVT-04 Approved Alvotech hf Jamteki, Uzpruvo, SELARSDI™ Japan Psoriasis Fuji Pharma Co Ltd 2023-09-25 Psoriasis; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease Details
Ustekinumab biosimilar(Amgen) ABP-654 Approved Amgen Inc Wezlana, WEZLANA United States Crohn Disease; Plaque psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative Amgen Inc 2023-10-31 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Ustekinumab biosimilar(Formycon) FYB-202 Phase 3 Clinical Formycon Psoriasis Details
Ustekinumab Biosimilar (qyuns) QX-001-S; HDM-3001; QX-001S Phase 3 Clinical Qyuns Therapeutics Co Ltd Psoriasis; Plaque psoriasis Details
Ustekinumab Biosimilar(Celltrion) CT-P43 Phase 3 Clinical Celltrion Inc Psoriasis Details
Ustekinumab biosimilar(Biocon) Phase 3 Clinical Biocon Biologics Ltd Psoriasis Details
Ustekinumab biosimilar(CSPC Pharma) SYSA-1902 Phase 3 Clinical Jushi Biopharmaceutical Co Ltd Psoriasis; Plaque psoriasis Details
Brazikumab AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) Phase 2 Clinical Amgen Inc Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease Details
anti-cancer mRNA therapeutics (Moderna Therapeutics) mRNA-2752 Phase 1 Clinical Moderna Inc, Astrazeneca Plc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
LY-900021 LY-900021 Phase 1 Clinical Halozyme Therapeutics Inc, Eli Lilly And Company Details
IL-23/CGRP bispecific antibody (Lilly) Phase 1 Clinical Eli Lilly And Company Autoimmune Diseases Details
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) Phase 1 Clinical Neuclone, Serum Institute Of India Ltd Autoimmune Diseases Details
Ustekinumab biosimilar(Rani Therapeutics) RT-111 Phase 1 Clinical Rani Therapeutics Llc Psoriasis Details
SOR-102 SOR-102 Phase 1 Clinical Sorriso Pharmaceuticals Inc Inflammatory Bowel Diseases; Colitis, Ulcerative Details
Ustekinumab biosimilar (BioFactura) BFI-751 Phase 1 Clinical BioFactura Australia Pty Ltd Psoriasis Details
Kagocel Clinical Nearmedic Plus Llc Respiratory Tract Infections; Respirovirus Infections; Influenza, Human Details
Ustekinumab biosimilar(Formycon) FYB-202 Phase 3 Clinical Formycon Psoriasis Details
Ustekinumab Biosimilar (qyuns) QX-001-S; HDM-3001; QX-001S Phase 3 Clinical Qyuns Therapeutics Co Ltd Psoriasis; Plaque psoriasis Details
Ustekinumab Biosimilar(Celltrion) CT-P43 Phase 3 Clinical Celltrion Inc Psoriasis Details
Ustekinumab biosimilar(Biocon) Phase 3 Clinical Biocon Biologics Ltd Psoriasis Details
Ustekinumab biosimilar(CSPC Pharma) SYSA-1902 Phase 3 Clinical Jushi Biopharmaceutical Co Ltd Psoriasis; Plaque psoriasis Details
Brazikumab AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) Phase 2 Clinical Amgen Inc Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease Details
anti-cancer mRNA therapeutics (Moderna Therapeutics) mRNA-2752 Phase 1 Clinical Moderna Inc, Astrazeneca Plc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
LY-900021 LY-900021 Phase 1 Clinical Halozyme Therapeutics Inc, Eli Lilly And Company Details
IL-23/CGRP bispecific antibody (Lilly) Phase 1 Clinical Eli Lilly And Company Autoimmune Diseases Details
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) Phase 1 Clinical Neuclone, Serum Institute Of India Ltd Autoimmune Diseases Details
Ustekinumab biosimilar(Rani Therapeutics) RT-111 Phase 1 Clinical Rani Therapeutics Llc Psoriasis Details
SOR-102 SOR-102 Phase 1 Clinical Sorriso Pharmaceuticals Inc Inflammatory Bowel Diseases; Colitis, Ulcerative Details
Ustekinumab biosimilar (BioFactura) BFI-751 Phase 1 Clinical BioFactura Australia Pty Ltd Psoriasis Details
Kagocel Clinical Nearmedic Plus Llc Respiratory Tract Infections; Respirovirus Infections; Influenza, Human Details

This web search service is supported by Google Inc.

totopphone